NCT05690204View on ClinicalTrials.gov

Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

February 28, 2025

Conditions
Gout
Interventions
DRUG

SAP-001

Test the efficacy and safety of SAP-001 versus placebo

Trial Locations (16)

20745

Maryland Site, Oxon Hill

27612

North Carolina Site, Raleigh

32713

Florida Site, DeBary

32789

Florida Site, Winter Park

33014

Florida Site, Miami Lakes

33173

Florida Site, Miami

Florida Site, Miami Lakes

39202

Mississippi Site, Jackson

75093

Texas Site, Plano

75150

Texas Site, Mesquite

77832

Texas Site, The Woodlands

80230

Denver Site, Denver

83713

Idaho Site, Boise

92119

California Site, San Diego

95821

California Site, Sacramento

00907

Puerto Rico Site, San Juan

All Listed Sponsors
lead

Shanton Pharma Pte. Ltd.

INDUSTRY